Chronic kidney disease and global cardiovascular risk in essential hypertension

Minerva Medica

Volumn 95, Issue 5, 2004, Pages 375-383

  Segura, J ^a   Campo, C ^a   Ruilope, L M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Blood; Cardiovascular diseases; Creatinine; Glomerular filtration rate; Hypertension; Microalbuminuria; Proteinuria; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; STATINE DERIVATIVE;

BODY WEIGHT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLUSTER ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SODIUM RESTRICTION;

ADULT; AGED; ALBUMINURIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; LIFE STYLE; MALE; PREVALENCE; PROGNOSIS; PROTEINURIA; RISK FACTORS;

EID: 8344233392     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Chobanian A, Bakris GL, Black HR, Cushman W, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-72.
2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
3. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46. Erratum in: Arch Intern Med 1998;158:573.
4. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46. Erratum in: Arch Intern Med 1998;158:573.
5. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.
6. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003;163:356-60.
7. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 1989;13 5 Suppl 180-93.
8. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001;12:218-25.
9. Ruilope LM, Palmer C, de Leeuw P, Morris BJ, Castaigne A, Rosenthal T et al. Evaluation of different parameters of renal function as predictors of primary outcome in the INSIGHT study. J Hypertens 2001;19 Suppl 2:S223.
10. De Leeuw P, Thijs L, Birkenhager WH, Voyaki S, Efstratopoulos AD, Fagard R et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from Syst-Eur trial. J Am Soc Nephrol 2002;13:2213-22.
11. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001;37:1069-74.
12. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic in the elderly program. Arch Intern Med 1998;158:1340-5.
13. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R et al. on behalf of the HOT Study Group. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens 2001;19:1149-59.
14. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
15. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001;161:886-91.
16. Luque M, Garcia-Robles R, Tamargo J, Ruilope LM. Blood pressure control in hospital located hypertension units. Hypertension 2001;37:1030.
17. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
18. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States. Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001;161:1207-16.
19. Kramer HJ, Nguyen QD, Curhan G, Hsu C. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-7.
20. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Levey AS, Bosch J, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
22. Lewis JB, Agodoa LE, Cheek D, Greene T, Middleton J, O'Connor D et al.; African-American Study of Hypertension and Kidney Disease. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 2001;38:774-53.
23. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002;39 Suppl 1:S1-S266.
24. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL et al. Level of kidney functions as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.
25. Henry RMA, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002;62:1402-7.
26. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five year follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol 1999;19:617-24.
27. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990;300:297-300.
28. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413-8.
29. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421-6.
30. Jensen JS, Feldt-Rasmussen B, Strangaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria and risk of ischemic heart disease. Hypertension 2000;35:898-903.
31. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325-33.
32. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997;80:164-9.
33. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PD et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001;103:3057-61.
34. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002;106:1777-82.
35. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002;20:353-5.
36. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002;16:79-89.
37. Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003;41:588-95.
38. Schmieder RE, Messerli FH, Garavaglia G, Nuñez B. Glomerular hyprefiltration indicates early target organ damage in essential hypertension. JAMA 1990;264:2775-80.
39. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003;21:1213-20.
40. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robies R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertens 1996;14:1259-63.
41. Pinto-Sietsma SJ, Janssen WMT, Hillege HL, Navis G, De Zeeuw D, De Jong PE. Urinary albumin excretion is associated with renal function abnormalities in a nondiabetic population. J Am Soc Nephrol 2000;11:1882-8.
42. Mann JFE, Gerstein HC, Qi-Long Y, Lonn EM, Hoogwerf BJ, Rashkow A et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized trial. J Am Soc Nephrol 2003;14:641-7.
43. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria. Am Heart J 1984;108:1347-52.
44. Samuelsson O. Hypertension in middle-aged man: management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand 1985;702 Suppl:1-79.
45. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
46. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725-8.
47. Mahon NG, Blackstone EH, Francis GS, Starling III RC, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002;40:1106-13.
48. Reis SE, Olson MB, Fried L, Reeser V, Mankad S, Pepine CJ et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation 2002;105:2826-9.
49. O'Brien MM, Gonzales R, Shroyer AL, Grunwald GK, Daley J, Henderson WG et al. Modest serum creatinine elevation affects adverse outcome after general surgery. Kidney Int 2002;62:585-92.
50. Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002;62:986-96.
51. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000;11:105-15.
52. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek R et al. Insulin resistance and hiperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-7.
53. Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T. Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. Clin Nephrol 2000;54:366-73.
54. Ribstein J, Du Cailar G, Mimran A. Glucose tolerance and age-associated decline in renal function of hypertensive patients. J Hypertens 2001;19:2257-64.
55. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-32.
56. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002;106:2800-5.
57. London GM, Guerin AP, Pannier B, Marchais SJ, Benetos A, Safar ME. Increased systolic pressure in chronic uremia: role of arterial wave reflection. Hypertension 1992;20:10-9.
58. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90.
59. Tinucci T, Abrahao SB, Santello JL, Mion D Jr. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001;15:401-6.
60. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-6.
61. Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003;107:1891-5.
62. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
63. Zoccali C, Menon V, Wang X, Greene T, Beck GJ, Kusek JW et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003;42:44-52.
64. De Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, for the PREVEND study group. Obesity and target organ damage: the kidney. Int J Obesity 2002;26 Suppl 4:S21-4.
65. Pinto-Sietsma SJ, Navis G, Janssen WMT, de Zeeuw D, Gans ROB, de Jong PE, for the PREVEND study group. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003;41:733-41.
66. Bursztyn M, Motro M, Grossman E, Shemesh J. Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. J Hypertens 2003;21:1953-9.
67. de la Sierra A, Bragulat E, Sierra C, Gomez-Angelas E, Antonio MT, Aguilera MT et al. Microalbuminuria in essential hypertension: clinical and biochemical profile. J Biomed Sci 2000;57:287-91.
68. Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E et al. Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J Hypertens 2002;20:1315-21.
69. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781-8.
70. Dell'Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002;40:1-8.
71. Verhave JC, Hillege HL, Burgerhof JGM, Navis G, De Zeeuw D, De Jong PE, for the PREVEND study group. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 2003;14:1330-5.
72. Segura J, Campo C, Roldan C, Christiansen H, Vigil L, Garcia-Robles R et al. Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol 2004;15: Suppl 1:S37-42.
73. Coresh J, Astor BC, Green T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
74. De Jong PE, Hillege HL, Pinto-Sietsma SJ, De Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transplant 2003;18:10-3.
75. Guyton AC, Coleman TG, Cowley AW Jr, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation in hypertension. Am J Med 1972;52:584-94.
76. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8.
77. Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of hypertension? Hypertension 1994;23:3-9.
78. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-23.
79. Strazzullo P, Galletti F, Barba G. Altered renal handling of sodium in human hypertension. Short review of the evidence. Hypertension 2003;41:1000-5.
80. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al., for the African-American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering progression and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
81. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggresive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
82. Schrier RW, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosoma-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733-9.
83. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003;14:881-7.
84. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
85. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004;15:1616-22.
86. Segura J, Campo C, Rodicio JL, Ruilope LM. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 2001;38(Pt 2):645-9.
87. Nakao N, Yoshimura A, Morita H, Takada M, Kavano T, Ideura T. Combination treatment of angiotensin II-receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
88. National Kidney Foundation K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003;41 Suppl 3: S1-77.